What is ELIGARD® (leuprorelin acetate)?

ELIGARD® is indicated for the palliative treatment of advanced prostate cancer.1 ELIGARD® is a sterile polymeric matrix formulation of leuprorelin acetate for subcutaneous injection. It is designed to deliver leuprorelin acetate at a controlled rate over a therapeutic period.1

THE POWER OF CHOICE1‡

‡ Choice of 1-month (7.5 mg), 3-month (22.5 mg) 4-month (30 mg) or 6-month (45 mg) injections.1

Only ELIGARD® offers a choice of 1, 3, 4 and 6-monthly dosages,1 giving you the flexibility to tailor treatment to suit the specific requirements of each of your patients.

ELIGARD product shot

Reliable and sustained testosterone
suppression at 4 doses1

Serum testosterone suppression is comparable to bilateral orchidectomy.1

In clinical trials, ELIGARD® suppressed serum testosterone to ≤50 ng/dL in:1

  • 94.1% of patients receiving ELIGARD® 1-monthly by day 28, and in 100% by day 422
  • 99% of patients receiving ELIGARD® 3-monthly by day 28, and in 100% by day 353
  • 96% of patients receiving ELIGARD® 4-monthly by day 28, and in 100% by day 424
  • 99% of patients receiving ELIGARD® 6-monthly by day 285

Serum testosterone levels following injection with ELIGARD® 1-5

Serum Testosterone levels following Adapted from the ELIGARD Product Information.1

ELIGARD®/Atrigel® delivery system

ELIGARD® (leuprorelin acetate), indicated for palliative treatment of advanced prostate cancer, incorporates the Atrigel® delivery system.1

After injection, the Atrigel®/leuprorelin acetate mixture forms a solid drug delivery depot, slowly releasing leuprorelin acetate over a controlled period of time.1

Biodegradable The Atrigel® implant is fully biodegradable and therefore does not require removal prior to the next injection.1

Ease of injection The Atrigel® liquid formulation allows for small injection volumes and uses standard needles and syringes for ease of administration.6

Biocompatible All components of the Atrigel® system are biocompatible and each has established safety and toxicity profiles.1

Adapted from Patel 2010.6

Convenience1 - Small delivery volumes, short needles

ELIGARD's short needle size and small delivery volume make it highly acceptable to patients.8

Comparison of LHRH agonists1,8-10

Convenience - small volumes, short needles
References:
  1. ELIGARD® Product Information.
  2. Perez-Marreno R et al. Clin Ther 2002; 24: 1902-14.
  3. Chu FM et al. J Urol 2002; 168: 119-203.
  4. Sartor O et al. Urology 2003; 62: 319-23.
  5. Crawford ED et al. J Urol 2006; 175: 533-6.
  6. TOLMAR Australia Data on file May 2015.
  7. Patel DB. J Global Pharma Technology 2010; 2: 85-90.
  8. Berges R. Eur Urol Suppl 2005; 4: 20-5.
  9. Zoladex 3.6 mg and Zoladex 10.8mg Product Information.
  10. Lucrin and Lucrin Depot Product Information.

PBS Information: Authority Required (STREAMLINED) Locally advanced
(equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate.

Please review full Product Information before prescribing.
Click here to view.

ELIGARD® Minimum Product Information: INDICATIONS: Palliative treatment of advanced prostate cancer. Treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy. DOSAGE: One subcutaneous injection of Eligard® every one/three/four/six months. Do not inject in the arm. CONTRAINDICATIONS: Hypersensitivity to GnRH, GnRH agonist analogues or any excipients; pregnancy (Category D) and lactation; paediatric patients; previous orchiectomy; sole treatment in patients with spinal cord compression or evidence of spinal metastases. PRECAUTIONS: Transient increase in serum testosterone causing bone pain, neuropathy, haematuria, urinary tract obstruction; spinal cord compression and/or ureteral obstruction; hypogonadism; metastatic vertebral lesions; hyperglycemia and diabetes; cardiovascular risk factors, QT interval prolongation; changes in bone density; convulsions. INTERACTIONS: Medicinal products known to prolong QT interval or Torsade de Pointes such as Class IA, III antiarrythmics, methadone, moxifloxacin, antipsychotics. ADVERSE EFFECTS: Flare phenomenon; injection site reaction; malaise, fatigue; dizziness; weakness; lethargy; syncope; rigors; alopecia; pruritis; myalgia; arthralgia; limb pain; atrophy, or pain of testes; decreased libido; gynaecomastia; reduced penile size; musculoskeletal disorders; nervous system disturbances; insomnia; depression; hot flashes/sweats; haematologic disorders; urinary disorders; gastrointestinal disorders; nausea; weight increase; cardiovascular disorders. See full PI for full list of adverse effects. Based on PI Oct 2017.

Information for your patients

"Prostate Cancer - information for you and your family"

Request copies